Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Eckert & Ziegler and Telix Partner to Support Phase III Prostate Cancer Study with Advanced Radiopharmaceutical Manufacturing

(IN BRIEF) Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization for Telix’s ProstACT GLOBAL Phase III study. The agreement includes supplying patients from Eckert & Ziegler’s Berlin facility and … Read the full press release

Evotec and Bristol Myers Squibb Strengthen Molecular Glue Partnership with $75 Million Milestone Payments

(IN BRIEF) Evotec SE has made significant progress in its strategic partnership with Bristol Myers Squibb, focused on developing a molecular glue-based therapy pipeline. This success has led to $75 million in milestone payments to Evotec. The partnership, which began … Read the full press release

Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer Treatment

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu has received conditional approval in China for treating locally advanced or metastatic HER2-positive gastric cancer, following promising results from the DESTINY-Gastric06 trial. This marks the third approval for Enhertu in China in less … Read the full press release

New Technique Promises to Improve Drug Delivery and Reduce Injections for Cancer and HIV Patients

(IN BRIEF) Professor Remco Tuinier and his team at Eindhoven University of Technology have developed a new method to slow the release of protein-based drugs, addressing the challenge of rapid dispersion in the body. By using polyethylene glycol (PEG) and … Read the full press release

Tubulis Recognized as One of 2024’s “Fierce 15” Biotechnology Companies by Fierce Biotech

(IN BRIEF) Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech. This recognition celebrates Tubulis’ innovative work in ADC development and its commitment to improving cancer treatment outcomes. With significant recent advancements, including a €128 … Read the full press release

MorphoSys Finalizes Delisting from Frankfurt and Nasdaq Markets Following Novartis Acquisition

(IN BRIEF) MorphoSys AG has completed its voluntary delisting from the Frankfurt Stock Exchange and Nasdaq Global Market following its acquisition by Novartis. The delisting agreement, announced on June 20, 2024, and the subsequent delisting purchase offer by Novartis were … Read the full press release

Roche Completes Acquisition of LumiraDx’s Point of Care Technology, Enhancing Global Diagnostic Capabilities

(IN BRIEF) Roche has completed the acquisition of LumiraDx’s Point of Care technology after receiving all necessary antitrust and regulatory clearances. This addition enhances Roche’s diagnostics portfolio with an advanced multi-assay platform that consolidates a wide range of tests, including … Read the full press release

Merck and GTRI Collaborate on Advanced Gene Therapy Production for Parkinson’s Disease

(IN BRIEF) Merck has signed an MoU with Gene Therapy Research Institution Co., Ltd. (GTRI) to support the production of gene therapy for Parkinson’s Disease using Merck’s Sf-RVN® Insect Cell Line platform. This collaboration aims to enhance the manufacturing process … Read the full press release

Expanded Partnership Between Just – Evotec Biologics and Sandoz Enhances Biosimilar Development and Supply Security

(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ … Read the full press release

EIB Invests €37.5 Million in Nyxoah’s Innovative Sleep Apnea Solutions

(IN BRIEF) The European Investment Bank (EIB) has awarded Belgium-based medtech company Nyxoah €37.5 million in venture-debt financing to support the development of innovative treatments for obstructive sleep apnea (OSA). This funding, backed by the InvestEU Life Sciences programme, will … Read the full press release

SGS Expands Biopharmaceutical Services with New Stability Studies Capabilities in Birsfelden Laboratory

(IN BRIEF) SGS has expanded its laboratory in Birsfelden, Switzerland, to offer comprehensive stability studies as part of its biopharmaceutical service portfolio. Effective February 2024, the enhanced facility provides integrated services including controlled temperature storage and various analytical tests, ensuring … Read the full press release

Roche Launches Advanced Diagnostic Test for B-Cell Lymphoma Detection

(IN BRIEF) Roche has introduced the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, the first clinically approved in-situ hybridisation (ISH) test of its kind. Designed to enhance sensitivity in diagnosing B-cell lymphoma, the assay helps differentiate cancerous … Read the full press release

Merck and Michael J. Fox Foundation Collaborate to Advance Parkinson’s Research with Innovative Biomarker Technology

(IN BRIEF) Merck and The Michael J. Fox Foundation (MJFF) are collaborating to advance Parkinson’s disease research using Merck’s SMCxPRO® immunoassay technology. This initiative aims to detect biomarkers indicating cell dysfunction in PD patients, enhancing research into new treatment options … Read the full press release

QIAGEN Launches Enhanced QCI Interpret for High-Throughput NGS Labs

(IN BRIEF) QIAGEN has launched an upgraded version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), tailored for high-throughput next-generation sequencing (NGS) labs. The new release enhances performance metrics like turnaround time and diagnostic yield through … Read the full press release

Merck’s Darmstadt Expansion: New €62 Million Facility to Elevate Quality Standards in Life Science

(IN BRIEF) Merck is investing €62 million in a new quality control facility at its Darmstadt headquarters as part of a larger €1.5 billion investment program. Scheduled for completion by mid-2025, the state-of-the-art facility will consolidate 135 employees into a … Read the full press release

Swissport’s Frankfurt Air Cargo Center Renews CEIV Pharma Certification, Affirming Commitment to Quality Handling

(IN BRIEF) Swissport’s air cargo center at Frankfurt Airport has once again earned CEIV Pharma certification from IATA, highlighting its commitment to excellence in handling pharmaceutical products. This certification reaffirms Swissport’s dedication to maintaining high-quality standards in pharmaceutical logistics, supporting … Read the full press release

Breakthrough Phase II Trial Data Reinforces Potential of Survodutide as Leading MASH Treatment

(IN BRIEF) In a significant stride towards combating metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim unveils groundbreaking results from a Phase II trial sub-analysis of survodutide. Demonstrating impressive efficacy, up to 64.5% of adults with moderate to advanced fibrosis stages F2 … Read the full press release

Schnelldorf Facility Upgrade: Merck Boosts Life Science Distribution Capacity

(IN BRIEF) Merck, a leading science and technology company, has inaugurated its expanded Life Science distribution center in Schnelldorf, Germany, following a €180 million investment that nearly doubled its size to 25,000 square meters. The upgraded facility now includes manual … Read the full press release

Novartis Unveils Long-Term Efficacy of Remibrutinib in Chronic Spontaneous Urticaria at EAACI Congress

(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release

Evotec Collaborates with Inserm and Lille University Hospital to Advance Obesity and Metabolic Disease Research

(IN BRIEF) Evotec SE announces a partnership with Inserm, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic markers in obesity and metabolic diseases. The collaboration, centered around the ABOS/DIABOMICS study led by Lille University Hospital, … Read the full press release